Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01179568 · ClinicalTrials.gov registry record · Phase 2
A Study of Medication With or Without Psychotherapy for Complicated Grief
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 395
- Enrollment target
NCT01179568: Completed Phase 2 study, sponsored by New York State Psychiatric Institute.
NCT01179568 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 395 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (197% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01179568, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 395 participants
- Enrollment target
Study Summary
The major goal of this 4-site, double blind, placebo-controlled intervention trial is to assess the efficacy of medication (Citalopram) alone or with psychotherapy (Complicated Grief Therapy) to treat the symptoms of complicated grief.
Primary Outcome
Brief rating scale frequently used in clinical trials. For this study, version modified for complicated grief was be used. Response is defined as a score of 1(very much improved) or 2 (much improved) on the scale. The rating was done by an Independent Evaluator.
Interventions
- OTHER Placebo
- DRUG Citalopram
- BEHAVIORAL Complicated Grief Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
What the finished NCT01179568 record still lists
NCT01179568 is an interventional study that assigns participants to a tested intervention. The registered 395 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (197% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01179568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01179568 about?
NCT01179568 is a clinical study titled "A Study of Medication With or Without Psychotherapy for Complicated Grief". The major goal of this 4-site, double blind, placebo-controlled intervention trial is to assess the efficacy of medication (Citalopram) alone or with psychotherapy (Complicated Grief Therapy) to treat the symptoms of complicated grief.
What is the current status of trial NCT01179568?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 395 participants. The study started on 2010-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01179568?
The interventions under investigation include: Placebo (OTHER), Citalopram (DRUG), Complicated Grief Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT01179568?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01179568's enrollment target sits among peer trials
395 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia